holds patents in the U.S., E.U., Japan, Australia, and pending in Canada, underscoring its global leadership in this innovation.

At the forefront of Conexeu's portfolio is Ten Minute Tissue™, a liquid dermal extracellular matrix (ECM) that remains fluid at room temperature and transitions into a gel at body temperature (~37°C). This unique thermosensitive scaffold promotes cell migration, proliferation, differentiation and new tissue formation, enabling seamless integration into host tissue. Clinically proven in pilot studies, Ten Minute Tissue™ accelerates wound healing compared to market leaders, while reducing inflammation and supporting rapid, non-fibrotic healing, reducing the risk of scarring. With its innovative collagen IP platform, Conexeu has the potential to bridge the gap between dermal fillers, biostimulators, and tissue repair, offering a category-defining opportunity in the multi-billion-dollar aesthetics and tissue engineering markets.

Ten-Minute Tissue™ is an investigational product and has not been cleared or approved by any regulatory authority. For more information, visit www.conexeu.com.